Adoption of the income statement and the balance sheet and the consolidated income statement and the consolidated balance sheet

The Annual General Meeting resolved to approve balance sheets and income statements for the financial year 2021.

Allocation of the company's profit/loss according to the adopted balance sheet

The Annual General Meeting resolved, in accordance with the Board's proposal, that no dividend shall be paid and the disposable funds of SEK 121 465 554 comprising the following (Share premium reserve of 866 017 483 less Profit/Loss carried forward -509 958 894 less Profit/Loss for the year of -234 593 035) will be carried forward to a new account.

Discharge from liability for the directors and the managing director

The Annual General Meeting did not grant discharge from liability for former CEO Henrik Norström. Otherwise the CEOs and board members were granted discharge from liability.

Board and auditors

The Annual General Meeting resolved to re-elect Clas Lindbergson, Åsa Sjöblom Nordgren, Karin O'Connor and Christer Trägårdh as ordinary board members and to elect Johnny Ludvigsson. Christer Trägårdh was appointed Chairman of the Board.

During the years 1985-1991, Johnny Ludvigsson was Secretary General of the International Society for Pediatric and Adolescent Diabetes, the world organization for childhood and adolescent diabetes. He has received, among other things, the Novo Nordisk Foundation's award for diabetes research in 1998 and the Inaugural ISPAD Prize in 2001 and has been appointed to Honorary Member of EASD, Honorary Member of ISPAD, and an honorary member of the Swedish Diabetology Association. He was named Diabetologist of the Year in 2009, and in 2014 was awarded the Knud Lundbæck Award by the Scandinavian Society for the Study of Diabetes. To date, Johnny Ludvigsson has published more than 500 articles, and every year the Child Diabetes Foundation awards two prizes in Johnny Ludvigsson's name to prominent child diabetes researchers in the Nordic countries and in Sweden.

The Annual General Meeting re-elected the accounting company Öhrlings PricewaterhouseCoopers AB as auditor.

The Annual General Meeting resolved that each of the board members, who are not employees of the company, shall receive a fee of SEK 300,000 except for the chairman of the board, who shall receive a fee of SEK 500,000.

Resolution on issue authorisation

The Annual General Meeting resolved, in accordance with what the Board had proposed, in short, that the Board shall be authorized to, on one or more occasions until the next annual general meeting, with or without regard of shareholders' pre-emption rights, and within the limits set out in the articles of association regarding share capital and number of shares, to resolve on issuance of shares, warrants and/or convertibles.

For further information, please contact:

Investor Relations
ir@brighter.se

Certified Adviser
Brighter's Certified Adviser är Mangold Fondkommission AB,
+46 8 5277 5020, ca@mangold.se, www.mangold.se.

About Brighter AB (publ)
Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is a key to providing smarter care for chronic conditions. Our daily-care solutions are designed with a vision to facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones, and their care providers - aiming to improve quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter's quality management system is ISO-13485 certified. In 2019 the company won the Swecare Rising Stars Award. The Company's shares are listed on Nasdaq First North Growth Market/BRIG.

For more information, please visit our website at https://brighter.se/.